2 2 Pharma Engineering Solutions Ltd 07043987 false 2024-11-01 2025-10-31 2025-10-31 The principal activity of the company is the design and manufacture of medical equipment. Digita Accounts Production Advanced 6.30.9574.0 true 07043987 2024-11-01 2025-10-31 07043987 2025-10-31 07043987 bus:Director1 1 2025-10-31 07043987 bus:Director2 1 2025-10-31 07043987 bus:OrdinaryShareClass1 bus:Non-cumulativeShares 2025-10-31 07043987 core:CurrentFinancialInstruments 2025-10-31 07043987 core:CurrentFinancialInstruments core:WithinOneYear 2025-10-31 07043987 bus:SmallEntities 2024-11-01 2025-10-31 07043987 bus:AuditExemptWithAccountantsReport 2024-11-01 2025-10-31 07043987 bus:FilletedAccounts 2024-11-01 2025-10-31 07043987 bus:SmallCompaniesRegimeForAccounts 2024-11-01 2025-10-31 07043987 bus:RegisteredOffice 2024-11-01 2025-10-31 07043987 bus:Director1 2024-11-01 2025-10-31 07043987 bus:Director1 1 2024-11-01 2025-10-31 07043987 bus:Director2 2024-11-01 2025-10-31 07043987 bus:Director2 1 2024-11-01 2025-10-31 07043987 bus:OrdinaryShareClass1 bus:Non-cumulativeShares 2024-11-01 2025-10-31 07043987 bus:PrivateLimitedCompanyLtd 2024-11-01 2025-10-31 07043987 core:Goodwill 2024-11-01 2025-10-31 07043987 core:Buildings 2024-11-01 2025-10-31 07043987 core:FurnitureFittings 2024-11-01 2025-10-31 07043987 countries:England 2024-11-01 2025-10-31 07043987 2024-10-31 07043987 bus:Director1 1 2024-10-31 07043987 bus:Director2 1 2024-10-31 07043987 2023-11-01 2024-10-31 07043987 2024-10-31 07043987 bus:Director1 1 2024-10-31 07043987 bus:Director2 1 2024-10-31 07043987 bus:OrdinaryShareClass1 bus:Non-cumulativeShares 2024-10-31 07043987 core:CurrentFinancialInstruments 2024-10-31 07043987 core:CurrentFinancialInstruments core:WithinOneYear 2024-10-31 07043987 bus:Director1 1 2023-11-01 2024-10-31 07043987 bus:Director2 1 2023-11-01 2024-10-31 07043987 bus:Director1 1 2023-10-31 07043987 bus:Director2 1 2023-10-31 xbrli:pure iso4217:GBP xbrli:shares

Registration number: 07043987

Pharma Engineering Solutions Ltd
Unaudited Filleted Abridged Financial Statements
for the Year Ended 31 October 2025

Pharma Engineering Solutions Ltd

Contents

Abridged Balance Sheet | 1 to 2
Notes to the Unaudited Abridged Financial Statements | 3 to 7

Pharma Engineering Solutions Ltd

(Registration number: 07043987)
Abridged Balance Sheet as at 31 October 2025

| Note | 2025 £ | 2024 £
Fixed assets |  |  |
Tangible assets | 5 | 3,577 | 5,754
Current assets |  |  |
Stocks |  | 500 | 500
Debtors |  | 22,088 | 31,228
Cash at bank and in hand |  | 2,762 | 9,226
|  | 25,350 | 40,954
Creditors: Amounts falling due within one year |  | (6,163) | (3,133)
Net current assets |  | 19,187 | 37,821
Total assets less current liabilities |  | 22,764 | 43,575
Provisions for liabilities |  | (219) | (313)
Accruals and deferred income |  | (1,500) | (1,499)
Net assets |  | 21,045 | 41,763
Capital and reserves |  |  |
Called up share capital | 6 | 2 | 2
Retained earnings |  | 21,043 | 41,761
Shareholders' funds |  | 21,045 | 41,763

Pharma Engineering Solutions Ltd

(Registration number: 07043987)
Abridged Balance Sheet as at 31 October 2025

For the financial year ending 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

All of the company’s members have consented to the preparation of an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

Approved and authorised by the Board on 6 July 2026 and signed on its behalf by:

......................................... B Jeffries Director

Pharma Engineering Solutions Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 October 2025

1 | General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
26 Harewood Avenue
Simonstone
Burnley
Lancashire
BB12 7JB

These financial statements were authorised for issue by the Board on 6 July 2026.

2 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Pharma Engineering Solutions Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 October 2025

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.
Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.
Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class | Depreciation method and rate
Improvements to leasehold | 10% pa on cost
Fixtures and fittings | 20% pa on cost

Goodwill

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date. Goodwill is amortised over its useful life, which shall not exceed ten years if a reliable estimate of the useful life cannot be made.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class | Amortisation method and rate
Goodwill | Over 5 years straight line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.
Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Pharma Engineering Solutions Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 October 2025

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.
The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3 | Staff numbers

The average number of persons employed by the company (including directors) during the year, was 2 (2024 - 2).

Pharma Engineering Solutions Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 October 2025

4 | Intangible assets

| Total £
Cost
At 1 November 2024 | 16,000
At 31 October 2025 | 16,000
Amortisation
At 1 November 2024 | 16,000
At 31 October 2025 | 16,000
Net book value
At 31 October 2025 | -
At 31 October 2024 | -

5 | Tangible assets

| Total £
Cost
At 1 November 2024 | 27,815
At 31 October 2025 | 27,815
Depreciation
At 1 November 2024 | 22,061
Charge for the year | 2,177
At 31 October 2025 | 24,238
Net book value
At 31 October 2025 | 3,577
At 31 October 2024 | 5,754

Pharma Engineering Solutions Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 October 2025

6 | Share capital

Allotted, called up and fully paid shares

| 2025 | 2024
| No. | £ | No. | £
Ordinary shares of £1 each | 2 | 2 | 2 | 2

7 | Related party transactions

Transactions with directors

2025 | At 1 November 2024 £ | Advances to director £ | Repayments by director £ | At 31 October 2025 £
B Jeffries
Director's loan | 13,817 | 6,653 | (14,000) | 6,470
Z M Jeffries
Director's loan | 13,817 | 6,653 | (14,000) | 6,470

2024 | At 1 November 2023 £ | Advances to director £ | At 31 October 2024 £
B Jeffries
Director's loan | - | 13,817 | 13,817
Z M Jeffries
Director's loan | - | 13,817 | 13,817